Gene Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene Symbol ARID1A
Synonyms B120 | BAF250 | BAF250a | BM029 | C1orf4 | CSS2 | ELD | hELD | hOSA1 | MRD14 | OSA1 | P270 | SMARCF1
Gene Description ARID1A, AT-rich interaction domain 1A, is a member of the cBaF subunit (PMID: 32303701) of the SWI/SNF chromatin remodeling complex and is involved in cell-cycle activation (PMID: 29136504). ARID1A has been reported to influence PI3K/AKT pathways (PMID: 24618703), and loss of function is commonly found in ovarian clear cell carcinoma (PMID: 32020380, PMID: 32027624), gastric, colorectal (PMID: 28937020), and bladder cancers (PMID: 28583311), while in liver cancer, Arida1a has a context dependent role (PMID: 29136504) and ARID1A promoter hypermethylation has been observed in squamous cell carcinoma (PMID: 32015157).
NCBI Gene ID Chromosome Map Location Canonical Transcript Gene Role
8289 1 1p36.11 NM_006015 Tumor suppressor (PMID: 30606230)

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03840967 Phase II Niraparib A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma Terminated USA 0
NCT04611139 Phase I Pembrolizumab + Seclidemstat Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers Withdrawn USA 0
NCT02576444 Phase II Adavosertib + Olaparib Olaparib Capivasertib + Olaparib Ceralasertib + Olaparib OLAParib COmbinations (OLAPCO) Terminated USA 0
NCT04633902 Phase II Olaparib + Pembrolizumab Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation Unknown status USA 0
NCT05986071 Phase Ib/II Fulvestrant + M1774 I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers (MATRIX) Not yet recruiting FRA 0
NCT04953104 Phase II Nivolumab Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression Recruiting USA 0
NCT05523440 Phase II Bevacizumab + Niraparib Niraparib Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation Recruiting USA 0
NCT02286687 Phase II Talazoparib Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes Active, not recruiting USA 0
NCT05039801 Phase I Bevacizumab + IACS-6274 + Paclitaxel IACS-6274 IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors Recruiting USA 0
NCT03718091 Phase II Berzosertib M6620 (VX-970) in Selected Solid Tumors Completed USA 0
NCT04493619 Phase Ib/II Carboplatin + PLX2853 PLX2853 PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer Terminated USA | CAN 0
NCT05687136 Phase I M1774 + Peposertib Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors Recruiting USA 0
NCT03925350 Phase II Niraparib Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation Unknown status USA 0
NCT04957615 Phase II Nivolumab Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression Recruiting USA 0
NCT04042831 Phase II Olaparib Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations Recruiting USA 0
NCT05023655 Phase II Tazemetostat Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation Recruiting USA 0
NCT03207347 Phase II Niraparib A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) Completed USA 0
NCT05490472 Phase Ib/II JAB-2485 JAB-2485 Activity in Adult Patients With Advanced Solid Tumors Recruiting USA 1
NCT05038839 Phase I Cabozantinib + Pamiparib Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors Active, not recruiting USA 0
NCT04779151 Phase II Dostarlimab-gxly + Niraparib Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (NIRADO) Suspended FRA 0
NCT05154994 Phase I Belinostat + Durvalumab + Tremelimumab Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancer Focus on Urothelial Carcinoma (RESOLVE) Suspended USA 0
NCT04170153 Phase I M1774 M1774 + Niraparib Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) Active, not recruiting USA | GBR | ESP 2
NCT04266912 Phase Ib/II Avelumab + Berzosertib Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors Active, not recruiting USA 0
NCT05010096 Phase I Copanlisib + Elimusertib BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors Withdrawn 0
NCT04985721 Phase II Pamiparib + Tislelizumab A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects (IMPARP-HRD) Recruiting AUS 0
NCT03568656 Phase Ib/II Atezolizumab + CCS1477 CCS1477 CCS1477 + Olaparib CCS1477 + Darolutamide Abiraterone + CCS1477 CCS1477 + Enzalutamide Study to Evaluate CCS1477 in Advanced Tumours Recruiting USA | SWE | NLD | GBR | FRA | ESP 0
NCT06518564 Phase II Avelumab + M1774 Avelumab and M1774 in ARID1A-mutated Endometrial Cancer (Prior IO) Recruiting USA 0
NCT02278250 Phase I VX-803 Carboplatin + VX-803 An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of M4344 (Formerly VX-803) as a Single Agent and in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors Completed USA | NLD | GBR | ESP 0
NCT03209401 Phase I Carboplatin + Niraparib Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies Terminated USA 0
NCT05338346 Phase I ATG-018 A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies (ATRIUM) Terminated AUS 0
NCT05379972 Phase II Olaparib + Pembrolizumab Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers Recruiting USA 0